1. Home
  2. TOI vs ACRS Comparison

TOI vs ACRS Comparison

Compare TOI & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo The Oncology Institute Inc.

TOI

The Oncology Institute Inc.

HOLD

Current Price

$3.46

Market Cap

327.6M

Sector

Health Care

ML Signal

HOLD

Logo Aclaris Therapeutics Inc.

ACRS

Aclaris Therapeutics Inc.

HOLD

Current Price

$3.71

Market Cap

311.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TOI
ACRS
Founded
2007
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Nursing Services
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
327.6M
311.0M
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
TOI
ACRS
Price
$3.46
$3.71
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
5
Target Price
$6.67
$9.75
AVG Volume (30 Days)
1.6M
2.4M
Earning Date
01-01-0001
05-27-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
69.01
EPS
N/A
N/A
Revenue
N/A
$1,683,000.00
Revenue This Year
$27.81
N/A
Revenue Next Year
$25.94
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.66
$1.05
52 Week High
$4.88
$4.89

Technical Indicators

Market Signals
Indicator
TOI
ACRS
Relative Strength Index (RSI) 67.24 60.99
Support Level $3.15 $2.67
Resistance Level $3.58 $3.78
Average True Range (ATR) 0.27 0.24
MACD 0.07 0.06
Stochastic Oscillator 92.71 89.40

Price Performance

Historical Comparison
TOI
ACRS

About TOI The Oncology Institute Inc.

The Oncology Institute Inc offers oncology services committed to improving cancer prevention, diagnosis, treatment, research, and education. The company provides services including infusion centres. In-house dispensary, Outpatient blood transfusion, Outpatient stem cell transplant, financial counseling, clinical trials, comprehensive lab testing, and end-of-life counseling. The business operates in three operating segments dispensary, patients services and clinical trials and others. Key revenue is earned from providing patient services. Majority of revenue is from patients services.

About ACRS Aclaris Therapeutics Inc.

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.

Share on Social Networks: